[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366458-105":59,"doc-detail-366458-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","innovative-logic-and-gate-gene-circuits-for-bladder-cancer-treatment-preclinical-study","Innovative logic - AND - gate gene circuits for bladder cancer treatment - preclinical study","","Precision oncology requires gene circuits that selectively target cancer cells while sparing normal tissues. Traditional single-gene targeting approaches often lack directed recognition and control across complex signaling networks. This preclinical study introduces the Logic “AND” Gate Dual-Target Genetic Circuit (LAG-DTGC), designed to integrate multiple aberrantly expressed biomarkers in bladder cancer cells. Detailed bioinformatics guided biomarker selection and circuit activation logic to trigger reprogramming only under abnormal expression. LAG-DTGC remodels cancer cell signaling to drive therapeutic effects and suggests a promising paradigm for more precise, less toxic bladder cancer treatment.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/innovative-logic-and-gate-gene-circuits-for-bladder-cancer-treatment-preclinical-study/366458/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/innovative-logic-and-gate-gene-circuits-for-bladder-cancer-treatment-preclinical-study/366458.png","ImageObject",300,407,{"name":92,"@type":93},"Grenda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study target in bladder cancer therapy?","Question",{"text":113,"@type":114},"Conventional treatments and single-gene targeted therapies have limited specificity and cannot comprehensively control complex signaling networks that drive bladder cancer progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does LAG-DTGC ensure selective activation in cancer cells?",{"text":118,"@type":114},"It is engineered to activate only when dual cancer-specific biomarkers are abnormally expressed, using a logic “AND” gate to trigger reprogramming under the required conditions.",{"name":120,"@type":111,"acceptedAnswer":121},"What preclinical results are highlighted for LAG-DTGC?",{"text":122,"@type":114},"The highlights report more than 60% apoptosis induction in bladder cancer cells while sparing normal tissues, and about a 70% reduction in tumor growth in preclinical mouse models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366458,1791101388,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Innovative logic “AND” gate gene circuits for bladder cancer treatment: preclinical study  \nChaojie Xu, MDa , Ying Dong, MDb,c,d , Dongchen Pei, MMede , Xintao Zhang, MDd , Xiaohong Han, BMedd , Congcong Cao, MDb,c,d , Baorui Wu, MDf , Changning Lv, MMeda , Zhengjun Kang, MMede ,*, Liqun Zhou, MDa ,*, Yuchen Liu, MDb,c ,*, Lin Yao, MDa ,*  \nAbstract  \nIn the evolving field of precision oncology, the synthesis of gene circuits that specifically target cancer cells while preserving normal tissue marks a significant breakthrough. However, traditional approaches typically concentrate on single-gene targets, lacking the directed recognition and control among the intricate networks of signaling pathways. Our study presents a synthetic gene circuit, the Logic “AND” Gate Dual-Target Genetic Circuit (LAG-DTGC), which integrates multiple signals to achieve comprehensive reprogramming of various signaling pathways in bladder cancer (BC) cells. This circuit’s development hinged on detailed bioinformatics analysis, pinpointing more unique biomarkers with similar expression pattern in BC. LAG-DTGC is engineered to selectively activate in cells where these biomarkers are abnormally expressed. Its precision and the remodeling cell behavior capability are further enhanced by incorporating a logic “AND” gate, triggering the circuit only in the presence of these aberrant cancer-specific biomarkers. LAG-DTGC exhibits an extraordinary ability to reprogram cancer cell signaling pathways, turning the cells’own mechanisms against them for therapeutic effect. This work highlights the potential of synthetic biology in developing precise, less toxic treatments for BC. The LAG-DTGC represents a promising new paradigm in cancer therapy.  \nKeywords: bladder cancer, cancer cell signaling, gene circuit, logic “AND” gate dual-target genetic circuit, synthetic biology  \nIntroduction  \nBladder cancer (BC) is one of the most aggressive human genitourinary cancers, has the highest published incidence involving malignant urinary system tumors[1] . Despite various therapeutic approaches, the clinical outcomes for BC have not improved significantly over the past 30 years, as the 5-year survival rates remain stagnant[2-4] . The primary limitations of conventional therapies, such as chemotherapy and radiotherapy, include severe side effects due to their lack of specificity, impacting not only cancer cells but also surrounding healthy tissues. These therapies are often ineffective at the molecular level for metastatic tumors, as they fail to address the complex signaling networks involved in cancer progression. Moreover, although targeted therapies were developed to address these issues by focusing on single-gene targets, they lack the ability to comprehensively modulate cancer’s signaling complexity. By merely targeting isolated molecular  \naDepartment of Urology, Peking University First Hospital, Peking University, Beijing, China, bShenzhen Institute of Translational Medicine, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen University, Shenzhen, China, cShenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China, dDepartment of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China, eDepartment of Urology, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan Province, China and fDepartment of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China  \nChaojie Xu, Ying Dong, Dongchen Pei, Xintao Zhang, and Xiaohong Han contributed equally to this manuscript.  \n*Corresponding authors. Address: Department of Urology, Peking University First Hospital, Peking University, Beijing, [China. E-mail: poparies@163.com](China. E-mail: poparies@163.com)","cbCait3ewVCEu5NJ","https://ap.wps.com/l/cbCait3ewVCEu5NJ","pdf",7863381,17,"English","# Abstract\n# Keywords\n# Introduction\n# Highlights\n## Preclinical outcomes and rationale","[{\"question\":\"What problem does the study target in bladder cancer therapy?\",\"answer\":\"Conventional treatments and single-gene targeted therapies have limited specificity and cannot comprehensively control complex signaling networks that drive bladder cancer progression.\"},{\"question\":\"How does LAG-DTGC ensure selective activation in cancer cells?\",\"answer\":\"It is engineered to activate only when dual cancer-specific biomarkers are abnormally expressed, using a logic “AND” gate to trigger reprogramming under the required conditions.\"},{\"question\":\"What preclinical results are highlighted for LAG-DTGC?\",\"answer\":\"The highlights report more than 60% apoptosis induction in bladder cancer cells while sparing normal tissues, and about a 70% reduction in tumor growth in preclinical mouse models.\"}]","Innovative logic - AND - gate gene circuits for bladder cancer treatment - preclinical study | PDF",1790165651,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a056a62e2c9b1569aae3a8c764c9277.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d53b5f4e34ec870374821ae3f178cd9c.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c8cfe6e9cb71db1aad629c04bd162fc.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c12c8d288b4998024eb885df09cd83fa.webp",980,1306]